Announcements Trials

Browse Landscape

Phase

Phase 2 7 Phase 3 5 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Ovarian Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10 human papillomavirus vaccine, L1 type 16, 18 7 olaparib 4 niraparib 4 Human Papillomavirus Recombinant Vaccine nonavalent 4 Vaccines 3 Saline Solution 3 Papillomavirus Vaccines 3 Medroxyprogesterone Acetate 3 Carboplatin 3 Bevacizumab 3 pegylated granulocyte colony-stimulating factor 2 liposomal doxorubicin 2 fluciclovine F-18 2 apatinib 2 Sevoflurane 2 Propofol 2 Paclitaxel 2 Aspirin 2 semaglutide 1 pegfilgrastim 1 pazopanib 1 palbociclib 1 lenvatinib 1 halofantrine 1 ganirelix 1 gadofosveset trisodium 1 fosaprepitant 1 follicle stimulating hormone, human, with HCG C-terminal peptide 1 ferrous gluconate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Trabectedin × Gynecologic × Clear all

NCT03164980 2025-03-20

COMPASS

North Eastern German Society of Gynaecological Oncology

Phase 4 Terminated

89 enrolled 20 charts

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡